194 related articles for article (PubMed ID: 32350909)
1. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Dash AB; Zhang J; Shen L; Li B; Berg D; Lin J; Avet-Loiseau H; Bahlis NJ; Moreau P; Richardson PG; Di Bacco A
Eur J Haematol; 2020 Sep; 105(3):274-285. PubMed ID: 32350909
[TBL] [Abstract][Full Text] [Related]
2. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
[TBL] [Abstract][Full Text] [Related]
3. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Di Bacco A; Bahlis NJ; Munshi NC; Avet-Loiseau H; Masszi T; Viterbo L; Pour L; Ganly P; Cavo M; Langer C; Kumar SK; Rajkumar SV; Keats JJ; Berg D; Lin J; Li B; Badola S; Shen L; Zhang J; Esseltine DL; Luptakova K; van de Velde H; Richardson PG; Moreau P
Eur J Haematol; 2020 Jul; 105(1):35-46. PubMed ID: 32145111
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
5. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
8. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T; Yamamura R; Ohta K; Kaneko H; Imada K; Nakaya A; Fuchida SI; Shibayama H; Matsuda M; Shimazu Y; Adachi Y; Kosugi S; Uchiyama H; Tanaka H; Hanamoto H; Shimura Y; Kanda J; Onda Y; Uoshima N; Yagi H; Yoshihara S; Hino M; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Kanakura Y; Nomura S
Eur J Haematol; 2021 Apr; 106(4):555-562. PubMed ID: 33476404
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
[TBL] [Abstract][Full Text] [Related]
12. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
[TBL] [Abstract][Full Text] [Related]
13. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
[TBL] [Abstract][Full Text] [Related]
16. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Iida S; Izumi T; Aotsuka N; Komeno T; Ishida T; Sunami K; Handa H; Berg D; Kase Y; Soeda J
Rinsho Ketsueki; 2018; 59(11):2399-2407. PubMed ID: 30531133
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
18. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Iida S; Izumi T; Komeno T; Terui Y; Chou T; Ikeda T; Berg D; Fukunaga S; Sugiura K; Sasaki M
Int J Clin Oncol; 2022 Jan; 27(1):224-233. PubMed ID: 34599726
[TBL] [Abstract][Full Text] [Related]
20. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
